Amendment ID: S3116-22

Amendment 22

Clarifying the Primary Care Expenditure Target

Mr. Tarr moves that the proposed new draft be amended in Section 8 by striking paragraphs (b)(1) through (b)(4), and replacing them with the following new language:-

(b)(1) For the calendar year 2028, the aggregate primary care expenditure target shall be equal to 9 per cent of total health care expenditures in the commonwealth, less spending on all pharmaceuticals, including medically-administered drugs and the primary care expenditure target shall be equal to 9 per cent of the total health care expenditures attributable to each health care entity. less spending on all pharmaceuticals, including medically-administered drugs.

(2) For the calendar year 2029, the aggregate primary care expenditure target shall be equal to 12 per cent of total health care expenditures in the commonwealth, less spending on all pharmaceuticals, including medically-administered drugs, and the primary care expenditure target shall be equal to 12 per cent of the total health care expenditures attributable to each health care entity, less spending on all pharmaceuticals, including medically-administered drugs.

(3) For the calendar year 2030, the aggregate primary care expenditure target shall be equal to 15 per cent of total health care expenditures in the commonwealth, less spending on all pharmaceuticals, including medically-administered drugs, and the primary care expenditure target shall be equal to 15 per cent of the total health care expenditures attributable to each health care entity, less spending on all pharmaceuticals, including medically-administered drugs.

(4) For calendar years 2031 and thereafter, if the commission determines that an adjustment in the aggregate primary care expenditure target and the primary care expenditure target is reasonably warranted, the commission may recommend modification to such targets; provided, however, that such targets shall not be lower than 15 per cent of total health care expenditures in the commonwealth, less spending on all pharmaceuticals, including medically-administered drugs.